Exciting News in Food Allergy Treatment!
Aquestive Therapeutics has announced an important FDA regulatory milestone for Anaphylm™ (dibutepinephrine) sublingual film.
Read the full announcement:
investors.aquestive.com/news-release...
#FoodAllergies #Anaphylaxis #Epinephrine #Anaphylm #Aquestive
Aquestive Therapeutics has announced an important FDA regulatory milestone for Anaphylm™ (dibutepinephrine) sublingual film.
Read the full announcement:
investors.aquestive.com/news-release...
#FoodAllergies #Anaphylaxis #Epinephrine #Anaphylm #Aquestive
October 15, 2026 at 10:51 PM
Exciting News in Food Allergy Treatment!
Aquestive Therapeutics has announced an important FDA regulatory milestone for Anaphylm™ (dibutepinephrine) sublingual film.
Read the full announcement:
investors.aquestive.com/news-release...
#FoodAllergies #Anaphylaxis #Epinephrine #Anaphylm #Aquestive
Aquestive Therapeutics has announced an important FDA regulatory milestone for Anaphylm™ (dibutepinephrine) sublingual film.
Read the full announcement:
investors.aquestive.com/news-release...
#FoodAllergies #Anaphylaxis #Epinephrine #Anaphylm #Aquestive
Aquestive Therapeutics moves R&D to HELIX in New Brunswick https://ift.tt/NlPgUXd
October 16, 2026 at 2:15 PM
Aquestive Therapeutics moves R&D to HELIX in New Brunswick https://ift.tt/NlPgUXd
October 15, 2026: the FDA accepted Aquestive's Anaphylm resubmission and set a PDUFA goal date of March 16, 2027. $AQST
https://www.merlintrader.com/aquestive-therapeutics-stock-hub/
https://www.merlintrader.com/aquestive-therapeutics-stock-hub/
Aquestive ($AQST): Anaphylm PDUFA March 16, 2027
Aquestive ($AQST): FDA accepted the Anaphylm NDA resubmission with a March 16, 2027 PDUFA date; cash, Libervant licensing and the risks ahead.
www.merlintrader.com
October 15, 2026 at 12:47 PM
October 15, 2026: the FDA accepted Aquestive's Anaphylm resubmission and set a PDUFA goal date of March 16, 2027. $AQST
https://www.merlintrader.com/aquestive-therapeutics-stock-hub/
https://www.merlintrader.com/aquestive-therapeutics-stock-hub/
AQST has licensed exclusive U.S. rights to LIBERVANT®, its seizure-rescue film, to #$ETON . Aquestive stays on as manufacturer and could earn milestones and royalties. Eton expects to launch in April 2027.
👇
prismmarketview.com/aquestive-ha...
👇
prismmarketview.com/aquestive-ha...
Aquestive Hands U.S. Rights to LIBERVANT to Eton as It Prepares for an April 2027 Launch
Aquestive Therapeutics (NASDAQ: AQST) has signed an exclusive U.S. licensing and supply agreement with Eton Pharmaceuticals (NASDAQ: ETON) for LIBERVANT® (diaz
prismmarketview.com
October 14, 2026 at 1:09 PM
AQST has licensed exclusive U.S. rights to LIBERVANT®, its seizure-rescue film, to #$ETON . Aquestive stays on as manufacturer and could earn milestones and royalties. Eton expects to launch in April 2027.
👇
prismmarketview.com/aquestive-ha...
👇
prismmarketview.com/aquestive-ha...
🚨 JUST IN: $ETON
Eton licenses LIBERVANT buccal film from Aquestive for $10M upfront, up to $47.5M milestones
#SEC #stocks #investing #ETON #Mergers
🔗 secwatch.observer
Eton licenses LIBERVANT buccal film from Aquestive for $10M upfront, up to $47.5M milestones
#SEC #stocks #investing #ETON #Mergers
🔗 secwatch.observer
October 14, 2026 at 12:08 PM
🚨 JUST IN: $ETON
Eton licenses LIBERVANT buccal film from Aquestive for $10M upfront, up to $47.5M milestones
#SEC #stocks #investing #ETON #Mergers
🔗 secwatch.observer
Eton licenses LIBERVANT buccal film from Aquestive for $10M upfront, up to $47.5M milestones
#SEC #stocks #investing #ETON #Mergers
🔗 secwatch.observer
#ETON #AQST Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazep…
https://www.stocktitan.net/news/ETON/eton-pharmaceuticals-and-aquestive-therapeutics-announce-exclusive-u-1bpjxas71sd1.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ETON/eton-pharmaceuticals-and-aquestive-therapeutics-announce-exclusive-u-1bpjxas71sd1.html?utm_source=stocktitan-bluesky&utm_medium=social
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 14, 2026 at 10:50 AM
#ETON #AQST Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazep…
https://www.stocktitan.net/news/ETON/eton-pharmaceuticals-and-aquestive-therapeutics-announce-exclusive-u-1bpjxas71sd1.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/ETON/eton-pharmaceuticals-and-aquestive-therapeutics-announce-exclusive-u-1bpjxas71sd1.html?utm_source=stocktitan-bluesky&utm_medium=social
#AQST Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
https://www.stocktitan.net/news/AQST/aquestive-therapeutics-announces-fda-acceptance-of-anaphylm-tm-nda-5za3njrhn8q9.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AQST/aquestive-therapeutics-announces-fda-acceptance-of-anaphylm-tm-nda-5za3njrhn8q9.html?utm_source=stocktitan-bluesky&utm_medium=social
Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
Aquestive Therapeutics (AQST) announced FDA acceptance of its Anaphylm application resubmission as complete, with a March 16, 2027 goal action date. The FDA classified the resubmission as a Class 2 response. Anaphylm is a dibutepinephrine film placed under the tongue, proposed for treating Type I allergic reactions, including anaphylaxis.The September 16, 2026 resubmission followed August announcements of positive topline results from human factors and pharmacokinetic studies, which assess use and drug movement through the body. Those studies addressed items raised in the FDA’s January 30, 2026 Complete Response Letter. Aquestive is advancing commercial preparations for a potential launch if approved and says its planned submission to Health Canada remains on track for Q4 2026.
www.stocktitan.net
October 15, 2026 at 11:00 AM
#AQST Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
https://www.stocktitan.net/news/AQST/aquestive-therapeutics-announces-fda-acceptance-of-anaphylm-tm-nda-5za3njrhn8q9.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/AQST/aquestive-therapeutics-announces-fda-acceptance-of-anaphylm-tm-nda-5za3njrhn8q9.html?utm_source=stocktitan-bluesky&utm_medium=social
$AQST 🏥
FDA accepted Aquestive Therapeutics, Inc.'s resubmission of the New Drug Application for Anaphylm (dibutepinephrine) sublingual film as a Class 2 response and set a PDUFA goal date of March 16, 2027.
Actionable market event
More market highlights:
https://rayvio.app/?utm_source=lifatpt
FDA accepted Aquestive Therapeutics, Inc.'s resubmission of the New Drug Application for Anaphylm (dibutepinephrine) sublingual film as a Class 2 response and set a PDUFA goal date of March 16, 2027.
Actionable market event
More market highlights:
https://rayvio.app/?utm_source=lifatpt
October 15, 2026 at 11:02 AM
$AQST 🏥
FDA accepted Aquestive Therapeutics, Inc.'s resubmission of the New Drug Application for Anaphylm (dibutepinephrine) sublingual film as a Class 2 response and set a PDUFA goal date of March 16, 2027.
Actionable market event
More market highlights:
https://rayvio.app/?utm_source=lifatpt
FDA accepted Aquestive Therapeutics, Inc.'s resubmission of the New Drug Application for Anaphylm (dibutepinephrine) sublingual film as a Class 2 response and set a PDUFA goal date of March 16, 2027.
Actionable market event
More market highlights:
https://rayvio.app/?utm_source=lifatpt
🚨 $AQST
On October 15, 2026, Aquestive Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for AnaphylmTM (dibutepinephrine) sublingual film for the treatment of Type I allergic r...
On October 15, 2026, Aquestive Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for AnaphylmTM (dibutepinephrine) sublingual film for the treatment of Type I allergic r...
SEC Filing: AQST
Click to view the official SEC document.
www.sec.gov
October 15, 2026 at 11:21 AM
🚨 $AQST
On October 15, 2026, Aquestive Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for AnaphylmTM (dibutepinephrine) sublingual film for the treatment of Type I allergic r...
On October 15, 2026, Aquestive Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has acknowledged its resubmission of the New Drug Application (NDA) for AnaphylmTM (dibutepinephrine) sublingual film for the treatment of Type I allergic r...
🚨 $AQST
On October 13, 2026, Aquestive Therapeutics, Inc. entered into a license agreement with Eton Pharmaceuticals, Inc. pursuant to which the Company granted Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film for the acute treatment of seizure clusters in patients wi...
On October 13, 2026, Aquestive Therapeutics, Inc. entered into a license agreement with Eton Pharmaceuticals, Inc. pursuant to which the Company granted Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film for the acute treatment of seizure clusters in patients wi...
SEC Filing: AQST
Click to view the official SEC document.
www.sec.gov
October 14, 2026 at 11:21 AM
🚨 $AQST
On October 13, 2026, Aquestive Therapeutics, Inc. entered into a license agreement with Eton Pharmaceuticals, Inc. pursuant to which the Company granted Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film for the acute treatment of seizure clusters in patients wi...
On October 13, 2026, Aquestive Therapeutics, Inc. entered into a license agreement with Eton Pharmaceuticals, Inc. pursuant to which the Company granted Eton exclusive U.S. rights to commercialize LIBERVANT® (diazepam) buccal film for the acute treatment of seizure clusters in patients wi...
Investigation Launched into Aquestive Therapeutics Following Significant Stock Decline#USA#San_Francisco#Schubert_Jonckheer#Aquestive_Therapeutics#Anaphylm
Investigation Launched into Aquestive Therapeutics Following Significant Stock Decline
Schubert Jonckheer is probing potential legal issues at Aquestive Therapeutics after a 37% drop in stock value. Investors encouraged to explore options.
third-news.com
October 7, 2026 at 2:26 PM
Investigation Launched into Aquestive Therapeutics Following Significant Stock Decline#USA#San_Francisco#Schubert_Jonckheer#Aquestive_Therapeutics#Anaphylm
Aquestive Therapeutics ($AQST): 13G holder update
Douglas K Bratton: now 0.6% (about $3M)
Counts convertible securities
SEC Schedule 13G/A · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Douglas K Bratton: now 0.6% (about $3M)
Counts convertible securities
SEC Schedule 13G/A · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Bratton Douglas K: 0.6% of Aquestive Therapeutics ($AQST)
Schedule 13G/A filed Oct 7. Who filed, the stake, and how it changed.
elixstocks.com
October 7, 2026 at 6:16 PM
Aquestive Therapeutics ($AQST): 13G holder update
Douglas K Bratton: now 0.6% (about $3M)
Counts convertible securities
SEC Schedule 13G/A · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Douglas K Bratton: now 0.6% (about $3M)
Counts convertible securities
SEC Schedule 13G/A · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Aquestive Therapeutics ($AQST): new 7.5% holder
Edward P Bass: 0 → 7.5% (about $43M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Edward P Bass: 0 → 7.5% (about $43M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Bass Edward P: 7.5% of Aquestive Therapeutics ($AQST)
Schedule 13G filed Oct 7. Who filed, the stake, and how it changed.
elixstocks.com
October 7, 2026 at 7:49 PM
Aquestive Therapeutics ($AQST): new 7.5% holder
Edward P Bass: 0 → 7.5% (about $43M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
Edward P Bass: 0 → 7.5% (about $43M)
13G: a passive investor, not seeking to influence the company
SEC Schedule 13G · filed Oct 7
#Investing #Stocks
Follow @elixstocksdata for daily institutional & insider activity.
AQST Q2 2026 earnings: Revenue $14M (+38.2%) · EPS $-0.18. Aquestive revenue rose 38% to $13.8M on higher Suboxone volumes and the operating loss narrowed to $8.2M, but an $11.7M charge for refinancing its 13.5% notes widened the net loss…
https://financialreportinsights.com/companies/aqst/2026/q2
https://financialreportinsights.com/companies/aqst/2026/q2
Aquestive Therapeutics, Inc. (AQST) Q2 2026 Earnings: Revenue $14M (+38.2%)
Aquestive revenue rose 38% to $13.8M on higher Suboxone volumes and the operating loss narrowed to $8.2M, but an $11.7M charge for refinancing its 13.5% notes widened the net loss to $22.9M ($0.18/share) ahead of a planned Q3 Anaphylm resubmission.
financialreportinsights.com
October 6, 2026 at 11:10 PM
AQST Q2 2026 earnings: Revenue $14M (+38.2%) · EPS $-0.18. Aquestive revenue rose 38% to $13.8M on higher Suboxone volumes and the operating loss narrowed to $8.2M, but an $11.7M charge for refinancing its 13.5% notes widened the net loss…
https://financialreportinsights.com/companies/aqst/2026/q2
https://financialreportinsights.com/companies/aqst/2026/q2
Anaphylm NDA resubmitted on September 17 after the January CRL.
Aquestive (#$AQST): Rich Daly Joins the Board — How Is the Company Preparing for Anaphylm?
www.merlintrader.com/aquestive-th...
Aquestive (#$AQST): Rich Daly Joins the Board — How Is the Company Preparing for Anaphylm?
www.merlintrader.com/aquestive-th...
Aquestive ($AQST): How Is It Preparing For Anaphylm?
$AQST: Aquestive appoints Rich Daly to its board from October 14. Anaphylm launch preparations, NDA resubmission and the distinction from FDA approval.
www.merlintrader.com
October 5, 2026 at 12:25 PM
Anaphylm NDA resubmitted on September 17 after the January CRL.
Aquestive (#$AQST): Rich Daly Joins the Board — How Is the Company Preparing for Anaphylm?
www.merlintrader.com/aquestive-th...
Aquestive (#$AQST): Rich Daly Joins the Board — How Is the Company Preparing for Anaphylm?
www.merlintrader.com/aquestive-th...
Aquestive (#$AQST): Rich Daly Joins the Board — How Is the Company Preparing for Anaphylm?
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/aquestive-th...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/aquestive-th...
Aquestive ($AQST): How Is It Preparing For Anaphylm?
$AQST: Aquestive appoints Rich Daly to its board from October 14. Anaphylm launch preparations, NDA resubmission and the distinction from FDA approval.
www.merlintrader.com
September 29, 2026 at 4:41 PM
Aquestive (#$AQST): Rich Daly Joins the Board — How Is the Company Preparing for Anaphylm?
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/aquestive-th...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/aquestive-th...
Aquestive Therapeutics, Inc. (0001398733) (Filer) (cik: 0001398733) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1398733/000139873326000052/0001398733-26-000052-index.htm
September 29, 2026 at 11:37 AM
Aquestive Therapeutics, Inc. (0001398733) (Filer) (cik: 0001398733) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1398733/000139873326000052/0001398733-26-000052-index.htm
🚨 $AQST
On September 29, 2026, Aquestive Therapeutics, Inc. announced that the Board of Directors of the Company has elected Richard J. Daly as a director of the Company, effective October 14, 2026. Mr. Daly will serve as a Class I director with a term expiring at the Company’s 2028 Annual Meetin...
On September 29, 2026, Aquestive Therapeutics, Inc. announced that the Board of Directors of the Company has elected Richard J. Daly as a director of the Company, effective October 14, 2026. Mr. Daly will serve as a Class I director with a term expiring at the Company’s 2028 Annual Meetin...
SEC Filing: AQST
Click to view the official SEC document.
www.sec.gov
September 29, 2026 at 11:22 AM
🚨 $AQST
On September 29, 2026, Aquestive Therapeutics, Inc. announced that the Board of Directors of the Company has elected Richard J. Daly as a director of the Company, effective October 14, 2026. Mr. Daly will serve as a Class I director with a term expiring at the Company’s 2028 Annual Meetin...
On September 29, 2026, Aquestive Therapeutics, Inc. announced that the Board of Directors of the Company has elected Richard J. Daly as a director of the Company, effective October 14, 2026. Mr. Daly will serve as a Class I director with a term expiring at the Company’s 2028 Annual Meetin...
🚨 $AQST
Aquestive Therapeutics, Inc. is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others.
Aquestive Therapeutics, Inc. is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others.
SEC Filing: AQST
Click to view the official SEC document.
www.sec.gov
September 25, 2026 at 12:00 PM
🚨 $AQST
Aquestive Therapeutics, Inc. is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others.
Aquestive Therapeutics, Inc. is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others.
Aquestive Secures $100M for Anaphylm Launch Following FDA Guidance
Aquestive Therapeutics is preparing for the U.S. commercial launch of its Anaphylm sublingual film. The company has s…
Read more: https://embers.news/article/aquestive-secures-100m-for-anaphylm-launch-following-fda-guidance-66657
Aquestive Therapeutics is preparing for the U.S. commercial launch of its Anaphylm sublingual film. The company has s…
Read more: https://embers.news/article/aquestive-secures-100m-for-anaphylm-launch-following-fda-guidance-66657
Aquestive Secures $100M for Anaphylm Launch Following FDA Guidance
Aquestive Therapeutics is preparing for the U.S. commercial launch of its Anaphylm sublingual film. The company has secured $100 million in dedicated funding while finalizing regulatory requirements for the epinephrine product. It expects to resubmit its application to the FDA in the third quarter o
embers.news
September 21, 2026 at 5:23 PM
Aquestive Secures $100M for Anaphylm Launch Following FDA Guidance
Aquestive Therapeutics is preparing for the U.S. commercial launch of its Anaphylm sublingual film. The company has s…
Read more: https://embers.news/article/aquestive-secures-100m-for-anaphylm-launch-following-fda-guidance-66657
Aquestive Therapeutics is preparing for the U.S. commercial launch of its Anaphylm sublingual film. The company has s…
Read more: https://embers.news/article/aquestive-secures-100m-for-anaphylm-launch-following-fda-guidance-66657
Aquestive resubmitted its FDA application for Anaphylm, a needle-free sublingual epinephrine film, after human factors and PK studies reduced pouch-opening time from 17 seconds to three.
Aquestive resubmits Anaphylm NDA after human factors and PK studies
Aquestive Therapeutics has refiled its FDA application for a needle-free sublingual epinephrine film after cutting pouch-opening time from 17 seconds to three.
biotech.disruptsmedia.com
September 21, 2026 at 6:06 AM
Aquestive resubmitted its FDA application for Anaphylm, a needle-free sublingual epinephrine film, after human factors and PK studies reduced pouch-opening time from 17 seconds to three.
Aquestive Therapeutics ($AQST) Stock Hub: Positive Anaphylm Studies Support the Q3 Resubmission Plan
https://merlintrader.com/aquestive-therapeutics-stock-hub/
https://merlintrader.com/aquestive-therapeutics-stock-hub/
Aquestive Therapeutics ($AQST) Stock Hub: Positive Anaphylm Studies Support The Q3 Resubmission Plan
Aquestive $AQST: Anaphylm Q3 resubmission plan, September conferences, Q2 financials, conditional funding and FDA risks.
merlintrader.com
September 18, 2026 at 9:32 AM
Aquestive Therapeutics ($AQST) Stock Hub: Positive Anaphylm Studies Support the Q3 Resubmission Plan
https://merlintrader.com/aquestive-therapeutics-stock-hub/
https://merlintrader.com/aquestive-therapeutics-stock-hub/
Aquestive Therapeutics (#$AQST) resubmits its NDA for Anaphylm, a needle-free epinephrine film, after addressing an FDA Complete Response Letter with new packaging and PK data. Redesigned pouch cuts opening time from 17 to 3 seconds. Still investigational.
prismmarketview.com/aquestive-re...
prismmarketview.com/aquestive-re...
September 17, 2026 at 12:57 PM
Aquestive Therapeutics (#$AQST) resubmits its NDA for Anaphylm, a needle-free epinephrine film, after addressing an FDA Complete Response Letter with new packaging and PK data. Redesigned pouch cuts opening time from 17 to 3 seconds. Still investigational.
prismmarketview.com/aquestive-re...
prismmarketview.com/aquestive-re...